Koji Harada
Department of Therapeutic Regulation for Oral Tumors
Institute of Health Biosciences
The University of Tokushima Graduate School
Tokushima 770-8504
Japan
Name/email consistency: high
- Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma. Harada, K., Sato, M., Ueyama, Y., Nagayama, M., Hamakawa, H., Nagahata, S., Yoshimura, Y., Osaki, T., Ryoke, K. Anticancer. Drugs (2008)
- Investigation of optimal schedule of concurrent radiotherapy with S-1 for oral squamous cell carcinoma. Harada, K., Ferdous, T., Yoshida, H. Oncol. Rep. (2007)
- S-1 inhibits tumorigenicity and angiogenesis of human oral squamous cell carcinoma cells by suppressing expression of phosphorylated Akt, vascular endothelial growth factor and fibroblast growth factor-2. Harada, K., Supriatno, , Kawashima, Y., Yoshida, H., Sato, M. Int. J. Oncol. (2007)
- High expression of Jun activation domain-binding protein 1 (Jab1) is a strong prognostic marker in oral squamous cell carcinoma patients treated by UFT in combination with radiation. Harada, K., Kawashima, Y., Yoshida, H., Sato, M. Anticancer Res. (2006)
- Thymidylate synthase expression in oral squamous cell carcinoma predicts response to S-1. Harada, K., Kawashima, Y., Yoshida, H., Sato, M. Oncol. Rep. (2006)
- High antitumor activity using intratumoral injection of plasmid DNA with mutant-type p27Kip1 gene following in vivo electroporation. Harada, K., Supriatno, , Kawaguchi, S., Onoue, T., Kawashima, Y., Yoshida, H., Sato, M. Oncol. Rep. (2005)
- Down-regulation of S-phase kinase associated protein 2 (Skp2) induces apoptosis in oral cancer cells. Harada, K., Supriatno, , Kawashima, Y., Itashiki, Y., Yoshida, H., Sato, M. Oral Oncol. (2005)
- High expression of S-phase kinase-associated protein 2 (Skp2) is a strong prognostic marker in oral squamous cell carcinoma patients treated by UFT in combination with radiation. Harada, K., Supriatno, , Kawaguchi, S., Kawashima, Y., Itashiki, Y., Yoshida, H., Sato, M. Anticancer Res. (2005)
- S-1, an oral fluoropyrimidine anti-cancer agent, enhanced radiosensitivity in a human oral cancer cell line in vivo and in vitro: involvement possibility of inhibition of survival signal, Akt/PKB. Harada, K., Kawaguchi, S., Supriatno, , Kawashima, Y., Yoshida, H., Sato, M. Cancer Lett. (2005)
- Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8. Harada, K., Supriatno, , Yoshida, H., Sato, M. Int. J. Oncol. (2005)
- Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Harada, K., Kawaguchi, S., Supriatno, , Onoue, T., Yoshida, H., Sato, M. Oral Oncol. (2004)
- Overexpression of iNOS gene suppresses the tumorigenicity and metastasis of oral cancer cells. Harada, K., Supriatno, , Kawaguchi, S., Tomitaro, O., Yoshida, H., Sato, M. In. Vivo (2004)
- Enhancement of apoptosis in salivary gland cancer cells by the combination of oral fluoropyrimidine anticancer agent (S-1) and radiation. Harada, K., Kawaguchi, S., Supriatno, , Onoue, T., Yoshida, H., Sato, M. Int. J. Oncol. (2004)
- Cepharanthine exerts antitumor activity on oral squamous cell carcinoma cell lines by induction of p27Kip1. Harada, K., Supriatno, , Yamamoto, S., Kawaguchi, S., Yoshida, H., Sato, M. Anticancer Res. (2003)
- Low p27Kip1 expression is associated with poor prognosis in oral squamous cell carcinoma. Harada, K., Supriatno, , Yoshida, H., Sato, M. Anticancer Res. (2002)
- Characteristics of antitumour activity of cepharanthin against a human adenosquamous cell carcinoma cell line. Harada, K., Bando, T., Yoshida, H., Sato, M. Oral Oncol. (2001)